RECRUITING

Registry for Systemic Eczema Treatments

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.

Official Title

Registry for Systemic Eczema Treatments

Quick Facts

Study Start:2024-01-17

Study Completion:2026-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06136767

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Year to 26 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Age \<26 years old * Current physician diagnosis of atopic dermatitis * Provide signed informed consent if ≥ 18 years old * Provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable * Subject and/or parent/legal guardian is willing to be contacted in the future by study staff * Seen for clinical care at Johns Hopkins since 1/1/2017 * Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy	* Age ≥26 years old at the time of registry enrollment * Does not speak English * If \<18 years old, has a primary caretaker who does not speak English * If \<18 years old, parent/legal guardian is unwilling to sign the written informed consent * Is a foster child * Has not received clinical care at Johns Hopkins since 1/1/2017

Inclusion Criteria

Exclusion Criteria

* Age \<26 years old
* Current physician diagnosis of atopic dermatitis
* Provide signed informed consent if ≥ 18 years old
* Provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable
* Subject and/or parent/legal guardian is willing to be contacted in the future by study staff
* Seen for clinical care at Johns Hopkins since 1/1/2017
* Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy

* Age ≥26 years old at the time of registry enrollment
* Does not speak English
* If \<18 years old, has a primary caretaker who does not speak English
* If \<18 years old, parent/legal guardian is unwilling to sign the written informed consent
* Is a foster child
* Has not received clinical care at Johns Hopkins since 1/1/2017

Contacts and Locations

Study Contact

Karin Kartawira, BA

CONTACT

667-290-4998

kkartaw1@jh.edu

Hsing-Jou Su, MD

CONTACT

929-217-8030

hsu28@jh.edu

Principal Investigator

Joy Wan, MD MSCE

PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Study Locations (Sites)

Johns Hopkins University

Baltimore, Maryland, 21218

United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

Joy Wan, MD MSCE, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-17

Study Completion Date2026-12-31

Study Record Updates

Study Start Date2024-01-17

Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

Atopic Dermatitis